Principal Investigator: Dr. Beno Huglin
Project leader/ Coordinator: Dr. Beno Huglin
Project Administrator: -
Funding Partner: IAVI (International AIDS Vaccine Initiative)
Start date: April 1, 2025
End date: May 31, 2028
MTBVAC TB Vaccine Study
This project aims to evaluate the efficacy, safety, and immunogenicity of the MTBVAC vaccine candidate in preventing tuberculosis (TB) among adolescents and adults aged 14-45 years, living in TB-endemic regions.
Study objectives
- To evaluate the protective efficacy of one dose of MTBVAC against bacteriologically confirmed pulmonary TB disease, not associated with HIV infection, diagnosed with sputum obtained before initiation of TB treatment, as compared to placebo.
- To assess the safety and reactogenicity of one dose of the MTBVAC candidate vaccine.
- To evaluate the impact of MTBVAC on the incidence of Subclinical TB developing in this cohort.
Funded by IAVI (International AIDS Vaccine Initiative), the project will be implemented by Ifakara Health Institute in Tanzania, with collaborating study sites in Kenya and South Africa. The study period is three years, starting from April 2025 until May 2028.